FDA Approval of Vepdegestrant#
Arvinas Inc. and Pfizer Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved vepdegestrant, branded as VEPPANU, for treating adults with a specific type of advanced breast cancer. This cancer is characterized by being estrogen receptor-positive and having certain mutations. The approval comes after patients have experienced disease progression following at least one line of endocrine therapy.
Clinical Trial Success#
The approval was based on results from the VERITAC-2 Phase 3 clinical trial, which involved 624 patients across 25 countries. This study compared vepdegestrant to fulvestrant, another treatment option. The findings showed that vepdegestrant reduced the risk of disease progression or death by 43% for patients with an ESR1 mutation. Patients taking vepdegestrant had a median progression-free survival of 5 months, compared to just 2.1 months for those on fulvestrant.
Financial Outlook#
Following the announcement, Arvinas' stock price rose to $10.27, marking a nearly 37% increase over the past year. The company has a market capitalization of $657 million, and some analysts believe it may be undervalued. However, it is important to note that Arvinas is quickly using up its cash reserves, although it currently has more cash than debt, indicated by a strong current ratio of 4.92.
Adverse Reactions and Future Plans#
Patients taking vepdegestrant may experience side effects, with the most common being decreased white blood cells, fatigue, and nausea. Most of these side effects were classified as mild to moderate (Grade 1-2). Looking ahead, Arvinas and Pfizer plan to partner with a third party for the commercialization of VEPPANU, with efforts to identify a partner already underway. Additionally, Arvinas has recently shared positive results from a Phase 1 trial for its Parkinson’s disease drug, ARV-102.